Article Versions Notes

Hörmann AA, Klingler M, Rangger C, Mair C, Joosten L, Franssen GM, Laverman P, von Guggenberg E. Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of ¹⁷⁷Lu-Labeled Peptide Analogs Targeting CCK2R. Pharmaceutics. 2023; 15(3):796. https://doi.org/10.3390/pharmaceutics15030796

Hörmann, Anton Amadeus, Maximilian Klingler, Christine Rangger, Christian Mair, Lieke Joosten, Gerben M. Franssen, Peter Laverman, and Elisabeth von Guggenberg. 2023. "Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of ¹⁷⁷Lu-Labeled Peptide Analogs Targeting CCK2R" Pharmaceutics 15, no. 3: 796. https://doi.org/10.3390/pharmaceutics15030796

Hörmann, A. A., Klingler, M., Rangger, C., Mair, C., Joosten, L., Franssen, G. M., Laverman, P., & von Guggenberg, E. (2023). Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of ¹⁷⁷Lu-Labeled Peptide Analogs Targeting CCK2R. Pharmaceutics, 15(3), 796. https://doi.org/10.3390/pharmaceutics15030796